Last reviewed · How we verify

Sarepta Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Sarepta Therapeutics, Inc. pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
SRP-4053 SRP-4053 phase 3 Antisense oligonucleotide Dystrophin pre-mRNA (exon 53) Neuromuscular/Genetic
SRP-9003 SRP-9003 phase 3 Antisense oligonucleotide DMPK mRNA Neuromuscular/Genetic Disorders
SRP-4045 SRP-4045 phase 3 Gene therapy Dystrophin gene Muscular dystrophy

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Abeona Therapeutics, Inc · 1 shared drug class
  2. AskBio Inc · 1 shared drug class
  3. Avidity Biosciences, Inc. · 1 shared drug class
  4. BioLab 612 LLC · 1 shared drug class
  5. Brain Neurotherapy Bio, Inc. · 1 shared drug class
  6. Emily de los Reyes · 1 shared drug class
  7. European Organisation for Research and Treatment of Cancer - EORTC · 1 shared drug class
  8. 4D Molecular Therapeutics · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sarepta Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Sarepta Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sarepta-therapeutics-inc. Accessed 2026-05-16.

Related